| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 1.03 [0.93, 1.15] | | < 1 | | 38% | 22 studies (20/2) | 26.4 % | moderate | critical | moderate | crucial | - |
| death or transfer to ICU | 0.79 [0.38, 1.63] | | < 1 | | 60% | 3 studies (2/1) | 73.9 % | serious | not evaluable | low | crucial | - |
| deaths | 0.83 [0.75, 0.92] | | < 1 | | 66% | 101 studies (80/21) | 100.0 % | moderate | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.82 [0.69, 0.98] | | < 1 | | 89% | 23 studies (13/10) | 98.7 % | serious | low | low | crucial | - |
| clinical deterioration | 0.85 [0.63, 1.14] | | < 1 | | 69% | 20 studies (16/4) | 86.4 % | moderate | low | moderate | important | - |
| clinical improvement | 1.16 [1.00, 1.33] | | > 1 | | 56% | 25 studies (23/2) | 97.5 % | moderate | low | moderate | important | - |
| clinical improvement (14-day) | 1.11 [0.94, 1.30] | | > 1 | | 47% | 19 studies (19/-) | 89.0 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.24 [1.03, 1.50] | | > 1 | | 54% | 9 studies (9/-) | 98.8 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.17 [1.00, 1.38] | | > 1 | | 45% | 16 studies (15/1) | 97.3 % | moderate | low | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.16 [1.04, 1.30] | | > 1 | | 56% | 19 studies (18/1) | 99.6 % | moderate | low | moderate | important | - |
| death or ventilation | 1.02 [0.96, 1.08] | | < 1 | | 3% | 10 studies (9/1) | 26.7 % | moderate | low | moderate | important | - |
| hospital discharge | 1.00 [0.93, 1.08] | | > 1 | | 41% | 21 studies (17/4) | 52.7 % | moderate | low | moderate | important | - |
| hospitalization | 0.37 [0.26, 0.51] | | < 1 | | 0% | 3 studies (2/1) | 100.0 % | critical | not evaluable | very low | important | - |
| mechanical ventilation | 0.90 [0.73, 1.11] | | < 1 | | 40% | 25 studies (24/1) | 83.1 % | moderate | critical | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.50 [0.13, 1.90] | | < 1 | | 68% | 3 studies (1/2) | 84.5 % | serious | not evaluable | low | important | - |
| radiologic improvement (14-day) | 1.37 [0.74, 2.54] | | > 1 | | 54% | 6 studies (6/-) | 84.2 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.45 [0.07, 3.02] | | > 1 | | 69% | 5 studies (5/-) | 20.8 % | some concern | serious | moderate | important | - |
| viral clearance | 1.35 [1.04, 1.76] | | > 1 | | 68% | 22 studies (20/2) | 98.7 % | moderate | critical | moderate | important | - |
| viral clearance (time to event analysis only) | 1.13 [0.90, 1.43] | | > 1 | | 61% | 12 studies (8/4) | 84.9 % | serious | critical | low | important | - |
| viral clearance by day 14 | 1.19 [0.93, 1.54] | | > 1 | | 58% | 16 studies (12/4) | 91.4 % | serious | low | low | important | - |
| viral clearance by day 7 | 1.13 [0.86, 1.47] | | > 1 | | 58% | 14 studies (14/-) | 80.9 % | some concern | low | moderate | important | - |
| ICU admission | 0.89 [0.66, 1.18] | | < 1 | | 32% | 16 studies (16/-) | 79.5 % | some concern | low | moderate | non important | - |
| off oxygenation | 0.98 [0.64, 1.51] | | > 1 | | 0% | 1 study (1/-) | 46.4 % | NA | not evaluable | | non important | - |
| recovery | 1.08 [0.91, 1.28] | | > 1 | | 65% | 7 studies (7/-) | 80.2 % | some concern | not evaluable | moderate | non important | - |
| severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| cardiac arrest | 1.91 [1.01, 3.62] | | < 1 | | 0% | 2 studies (1/1) | 2.3 % | serious | not evaluable | low | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 0.85 [0.71, 1.01] | | < 1 | | 0% | 23 studies (23/-) | 96.9 % | some concern | critical | moderate | important | - |
| abnormal ECG findings | 1.50 [0.88, 2.57] | | < 1 | | 0% | 1 study (-/1) | 7.0 % | NA | not evaluable | | non important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.67 [1.24, 2.23] | | < 1 | | 68% | 27 studies (27/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 1.16 [0.74, 1.80] | | < 1 | | 36% | 4 studies (3/1) | 26.0 % | moderate | not evaluable | moderate | non important | - |
| deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
